SHORT COMMUNICATION



Open Access

Inactivated Pseudomonas PE(ΔIII) exotoxin fused to neutralizing epitopes of PEDV S proteins produces a specific immune response in mice



Leqiang Sun^{1,2}, Yajie Tang^{1,3}, Keji Yan¹, Huanchun Chen^{1,2} and Huawei Zhang^{1,4*}

Abstract

Porcine epidemic diarrhea (PED) caused by the porcine epidemic diarrhea virus (PEDV), is a severe infectious and devastating swine disease that leads to serious economic losses in the swine industry worldwide. An increased number of PED cases caused by variant PEDV have been reported in many countries since 2010. S protein is the main immunogenic protein containing some B-cell epitopes that can induce neutralizing antibodies of PEDV. In this study, the construction, expression and purification of Pseudomonas aeruginosa exotoxin A (PE) without domain III (PE Δ III) as a vector was performed for the delivery of PEDV S-A or S-B. PE(Δ III) PEDV S-A and PE(Δ III) PEDV S-B recombinant proteins were confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot analysis. The immunogenicity of PEDV S-A and PEDV S-B subunit vaccines were evaluated in mice. The results showed that PEDV-S-B vaccine could not only induce specific humoral and Th1 type-dominant cellular immune responses, but also stimulate PEDV-specific mucosal immune responses in mice. PEDV-S-B subunit vaccine is a novel candidate mucosal vaccine against PEDV infection.

Keywords: Porcine epidemic diarrhea virus, S protein, Neutralizing antibody, Th1-type immune response

Main text

Porcine epidemic diarrhea (PED) caused by the porcine epidemic diarrhea virus (PEDV) is a highly contagious and devastating swine disease that leads to high mortality in piglets as it causes severe diarrhea, vomiting and dehydration (Gerdts and Zakhartchouk 2017; Reveles-Félix et al. 2020). PEDV belongs to the Alpha-coronavirus genus of the Coronaviridae family (Lee 2015; Wang et al. 2016; Liu et al. 2019). PEDV genome is a positive-sense and single-stranded RNA of approximately 28 kb in length. It comprises four

Full list of author information is available at the end of the article



structural proteins, namely, spike (S), envelope, membrane and nucleocapsid proteins, and three nonstructural proteins, namely, replicases 1a, replicases 1b and ORF 3 (Lee 2015; Sun et al. 2016). Since 2010, PEDV infection outbreaks in pigs have been reported in many Asian countries, including China, South Korea, and Japan (Park et al. 2013; Lee 2015; Park et al. 2018; Pizzurro et al. 2018; Sun et al. 2018; Wang et al. 2018; Liu et al. 2019; Liang et al. 2020; Chen et al. 2021). These outbreaks were caused by a new PEDV strain variant that differs from the classic European strain (CV777). Variant PEDV strains have been reported worldwide since 2010 (Lin et al, 2016; Wang et al. 2016; Guo et al. 2018; Liang et al. 2020; Reveles-Félix et al. 2020). Phylogenetic analysis has revealed that PEDV had two major genetic groups, namely, GI (classical) and GII (variant). GI and GII are further divided into two subgroups (GI-a and

© The Author(s). 2021, corrected publication 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

^{*} Correspondence: ZHW@mail.hzau.edu.cn

¹State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, Hubei, China

⁴College of Life Science and Technology, Huazhong Agricultural University, Wuhan 430070, Hubei, China

GI-b) and three subgroups (GII-a, GII-b, and GII-c) respectively (Guo et al. 2018).

PEDV S glycoprotein is a major immunogenic protein that induces high levels of neutralizing antibodies (Makadiya et al. 2016; Hou et al. 2018; Li et al. 2018a; Li et al. 2018b; Chen et al. 2021). It is also an important target antigen for the development of genetically engineered vaccines against PEDV infection. S protein is approximately 4161 bp long and encodes a protein of approximately 1387 amino acids (aa), which are divided into S1 and S2 subunits (Oh et al. 2014; Makadiya et al. 2016). Multiple neutralizing epitopes (499-638, 748-755, 764-771 and 1368-1374 aa) have been reported in S protein, and they play important roles in humoral immunity (Li et al. 2017; Hao et al. 2017; Liu et al. 2019). Previous studies also suggested that S10 subunit (19-210 aa) can induce neutralizing antibodies against PEDV and mainly neutralizes the infectivity of homologous PEDV strains (Li et al. 2017). Attenuated or inactivated PEDV vaccines based on isolated variant PEDV strains have been successfully developed in several countries (Collin et al. 2015; Lee et al. 2018; Chen et al. 2021). Many researchers have also developed PEDV subunit vaccines based on PEDV S protein (Makadiya et al. 2016; Ma et al. 2018; Li et al. 2018a; Li et al. 2018b).

Pseudomonas aeruginosa exotoxin A (PE) lacking domain III ($PE(\Delta III)$) is a nontoxic bioadjuvant that enhances cellular and humoral immune responses to a fused target gene (Chen et al. 2001; Liao et al. 2005; Yang et al. 2013). PE contains three domains, and domain III is toxic. As an immune adjuvant, PE(Δ III) fused with RR1 of Mycoplasma hyopneumoniae enhances specific immune responses (Chen et al. 2001). Chao-Wei Liao et al. (2005) reported that PE(Δ III), a carrier fused with human papillomavirus type 16 E7, increased the number of E7-specific CD8+ and CD4+ T-cell precursors and improved E7-specific antibodies (Liao et al. 2005). Therefore, PE(Δ III)-fused PEDV S protein can be used to develop subunit vaccines.

In the present study, $PE(\Delta III)$ was constructed, expressed and purified as a vector to deliver PEDV S-A (aa 25–229) or S-B (aa 499–789+ aa 1370–1378) gene segments of the epidemic PEDV isolates of genogroup GII-a. In Fig. 1a, *PEDV S-A* or *S-B* gene was fused with $PE(\Delta III)$ gene *PE(\Delta III) PEDV S-A* or *S-B* gene was fused with $PE(\Delta III)$ genes were synthesized by Sangon Biotech and cloned into the pET28a vector by restriction enzymes *Nhe*I and *Xho*I. The recombinant plasmids pET28-PE(ΔIII) PEDV S-A and pET28-PE(ΔIII) PEDVS-B were confirmed through restriction enzyme digestion and DNA sequencing.

The recombinant plasmids pET28-PE(Δ III) PEDV S-A and pET28-PE(Δ III) PEDVS-B were transformed into *E. coli* BL21 (DE3) pLys cells. Expression of the recombinant strains was induced by 1 mM IPTG and expressed as an inclusion body. After the inclusion bodies were denatured and renatured, the recombinant proteins were purified through Ni²⁺ affinity chromatography. The purified proteins were detected through SDS-PAGE (Fig. 1b)





and Western blot analyses (Fig. 1c). SDS-PAGE showed that the purified PE(Δ III) PEDV S-A and PE(Δ III) PEDV S-B were approximately 71 and 80.5 kDa, respectively. The specific bands were determined by His monoclonal antibody through Western blot.

To evaluate the specific humoral immunity of mice immunized with the recombinant proteins, indirect ELISA and neutralizing antibody tests were performed. Serum samples collected at 0, 14, 28, and 42 dpi (days post immunization) were examined by indirect ELISA. As showen in Fig. 2a, PEDV-specific IgG could be detected in mice immunized with PEDV S-A and PEDV S-B at 14 dpi. After mice were boosted with the vaccine, antibody titers of PEDV S-B group were significantly higher than those of PEDV S-A group (P > 0.05). In Fig. 2b, PEDV-specific IgA was detected in mice immunized with PEDV S-A and PEDV S-B at 28 and 42 dpi. PEDV-specific IgA level of PEDV S-B group was significantly higher than that of PEDV S-A group. In addition, PEDV-specific IgA in the intestinal contents of mice immunized with PEDV S-A or PEDV S-B was detected (Fig. 3a). IgA level of mice immunized with PEDV S-B was significantly higher than that of PEDV S-A group. Specific PEDV IgAs play an important role in PEDV vaccines. PEDV-specific neutralizing antibody could also be stimulated by immunization with PEDV S-A or PEDV S-B vaccine. The levels of neutralizing antibodies in PEDV S-B group were higher than those in PEDV S-A group (Fig. 3b). Specific IgA and neutralizing antibodies are important factors for providing protection against PEDV.

To characterize cell-mediated immune responses, PEDV-specific lymphocyte proliferation and cytokine profiles were determined. Proliferative responses of the lymphocytes stimulated by purified PEDV were observed in PEDV S-A and PEDV S-B groups but not in PBS group (Fig. 4). The stimulation index (SI) of PEDV S-A significantly differed among PEDV S-B groups. These results indicated that PEDV S-A and PEDV S-B could induce the proliferation of spleen lymphocytes in vitro. Th1-type (IFN-y and IL-2) and Th2-type (IL-4 and IL-10) cytokines were examined using a commercially available double-antibody sandwich ELISA kit. As showen in Fig. 5a and b, the highest concentrations of IFN-y and IL-2 were measured in PEDV S-B group (P < 0.001), and they were significantly higher than those of PEDV S-A group. In Fig. 5c and d, concentrations of IL-4 and IL-10 in PEDV S-A and PEDV S-B groups were significantly higher than those in PBS group. No significant difference was observed between PEDV S-A and PEDV S-B groups (P > 0.05). Cytokines play an important regulatory role in various immune reactions. These results demonstrated that PEDV S-B group could induce Th1-dominant cellular immune responses. Our results were consistent with previous studies, which showed that $PE(\Delta III)$ delivering antigen proteins improved cellular immune responses in vivo (Yang et al. 2013; Martínez et al. 2021).

Based on the above results, the purified PEDV S-A and PEDV S-B proteins could induce specific humoral and cellular immune responses in mice. PEDV-S-B could stimulate PEDV-specific immune responses in mice. This study indicates that PEDV-S-B subunit vaccine is a novel candidate subunit vaccine against PEDV infection. Further studies should be conducted to evaluate the immunoprotective effect of PEDV-S-B subunit vaccines in sows and piglets.

Methods

Cells and viruses

Vero cells (ATCC CCL-81) were cultured in Dulbecco's minimal essential medium (DMEM; Gibco, USA) with 10% fetal bovine serum (FBS; Gibco, USA) at 37 °C in 5% CO₂. PEDV CH2019 strain, which is the pandemic strain of genogroup GII-a, was isolated and stored in our









laboratory. PEDV CH2019 strain was propagated in Vero cells and used in the neutralization assay.

Construction of plasmids and protein expression and purification

PEDV S-A fused with PE(Δ III) (GenBank: K01397.1) or PEDV S-B from the variant PEDV CH2019 strain was codon optimized, synthesized by Sangon Biotech, and cloned into pET28a vector for recombinant protein expression. Two recombinant plasmids, namely, pET28-PE(Δ III) PEDV S-A and pET28-PE(Δ III) PEDV S-B, were successfully constructed and confirmed through DNA sequencing by Sangon Biotech.

The recombinant plasmids pET28-PE(Δ III) PEDV S-A and pET28-PE(Δ III) PEDV S-B were transformed into *E. coli* BL21 (DE3) pLys cells, and the recombinant proteins were purified by Ni²⁺ affinity chromatography.

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS–PAGE) and Western blot assays

After purification was performed, the proteins (PE(Δ III) PEDV S-A and PE(Δ III) PEDV S-B) were separated through 12% SDS-PAGE to detect the purity of target



proteins. The purified target proteins were also confirmed by Western blot analysis. Protein bands were detected using an ECL chemiluminescence system and visualized with Image Lab V. 4.0.1.

Mice immunization

Animal experiments were performed in accordance with protocols approved by the animal ethical and welfare committee of Huazhong Agricultural University. Sixweek-old female BALB/c mice were purchased from the Hubei Center of Disease Control, China. The mice were randomly divided into three groups (n = 20). Group A (negative control group) was intranasally (i.n.) immunized with 50 µL PBS; Group B was i.n. immunized with PEDV S-A, which was composed of 30 μ g purified PE Δ -III PEDV S-A; Group C was i.n. immunized with PEDV S-B, which was composed of 30 μ g purified PE(Δ III) PEDV S-B. After 2 weeks, all mice were boosted with the same vaccine. Serum samples were collected at 0, 14, 28, and 42 dpi and assayed for PEDV-specific IgG or IgA and PEDV-specific neutralizing antibodies. The small intestines of mice immunized with PEDV S-A and PEDV S-B groups were collected at 42 dpi. The extracted liquid was harvested by grinding and centrifuging, and it was assayed for PEDV-specific IgA.

Enzyme-linked immunosorbent assay

Ninety-six well microtitration plates were coated with 0.5 μ g purified PEDV diluted in 0.05 M NaHCO₃ with a sucrose discontinuous gradient and incubated at 4 °C overnight. The incubated plates were blocked with 2% BSA-PBST and washed three times with PBST. Samples were diluted (1: 200) with 2% BSA-PBST, added to the plates for 1 h at 37 °C, washed three times, and incubated with HRP-conjugated goat anti-mouse IgG (1: 5000; ABclonal, USA) or goat anti-mouse IgA (1: 4000; Southern Biotech, USA) for 1 h at 37 °C to detect



antibody titers of PEDV-specific IgG or IgA. The optical density (OD) was measured at 450 nm by using a microplate reader.

Neutralization assay

Serum neutralization test was performed to detect PEDV antibodies as previously described (Hou et al. 2018; Li et al. 2018a; Li et al. 2018b). Neutralizing antibody titers were calculated as the reciprocal of the highest dilution at which Vero cell infection was inhibited in 50% of the culture wells.

Lymphocyte proliferation assay

Splenic lymphocytes were separated from the spleen of immunized mice by using a mouse lymphocyte isolation reagent (TBD, Tianjin, China). The isolated lymphocytes were adjusted to 4×10^6 cells/mL, resuspended in RPMI-1640 containing 10% FBS, seeded into 96-well plates (100 µL/well), and stimulated with 5 µg purified PEDV, 10 µg/mL concanavalin A, or 100 µL RPMI 1640. Proliferative responses were detected with an MTS assay. OD was measured at 450 nm by using a microtiter plate reader. Stimulation index (SI) was calculated with the following formula: SI = (OD of immunized groups – OD of blank control)/(OD of negative control group – OD of blank control).

Cytokine assays

Splenic lymphocytes were isolated, resuspended at 4×10^{6} cells/mL with RPMI-1640 containing 10% FBS, seeded

into 24-well plates, and stimulated with 5 μ g/mL purified PEDV. After 24 h of incubation, culture supernatant was centrifuged at 1000 rpm for 10 min. Cytokines (IFN- γ , IL-2, IL-4, and IL-10) in the culture supernatant were analyzed with a commercial sandwich ELISA kit. OD was measured at 450 nm by using a microtiter plate reader.

Statistical analyses

Statistical analyses were performed with GraphPad Prism V. 5. Data were represented as the mean \pm SEM. One-way ANOVA was conducted to statistically analyze differences between multiple groups. Differences were considered significant when P < 0.05.

Abbreviations

PED: Porcine epidemic diarrhea; PEDV: Porcine epidemic diarrhea virus; PE: Pseudomonas aeruginosa exotoxin A; Th1: T helper (Th1) cells; E. coli: Escherichia coli; kDa: Kilodalton; ELISA: Enzyme-linked immunosorbent assay; IgA: Immunoglobulin A; SI: Stimulation index

Acknowledgement

We would like to thank the EssayStar for English language editing.

Authors' contributions

Designed the experiments: LS, HC and HZ; Performed the experiments: LS. and Y.; Analyzed the data: HZ; Wrote the paper: LS, and HZ; Proofed the manuscript: YT, KY and LS. All authors read and approved the final manuscript.

Funding

This research was funded by the National Natural Science Foundation of China (31900746 and 31802170), and Postdoctoral Science Foundation (2019M660182).

Availability of data and materials

Data will be shared upon request by the readers.

Declarations

Ethics approval and consent to participate

All experimental protocols were approved by the Research Ethics Committee of College of Veterinary Medicine (HZAUMO-2020-083) HZAUMO-2020-083, Huazhong Agricultural University, Hubei, China.

Consent for publication

Not applicable.

Competing interests

Author Huanchun Chen was not involved in the journal's review or decisions related to this manuscript. The authors declare no other conflict of interest.

Author details

¹State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, Hubei, China. ²Laboratory of Animal Virology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, Hubei, China. ³Henan Joint International Research Laboratory of Veterinary Biologics Research and Application, Anyang Institute of Technology, Anyang 455000, Henan, China. ⁴College of Life Science and Technology, Huazhong Agricultural University, Wuhan 430070, Hubei, China.

Received: 11 July 2021 Accepted: 17 August 2021 Published online: 08 October 2021

References

- Chen, J.R., C.W. Liao, S.J.T. Mao, and C.N. Weng. 2001. A recombinant chimera composed of repeat region RR1 of Mycoplasma hyopneumoniae adhesin with Pseudomonas exotoxin: In vivo evaluation of specific IgG response in mice and pigs. *Veterinary Microbiology* 80 (4): 347–357. https://doi.org/10.101 6/S0378-1135(01)00315-7.
- Chen, P., X. Zhao, S. Zhou, T. Zhou, X. Tan, X. Wu, W. Tong, F. Gao, L. Yu, Y. Jiang, H. Yu, Z. Yang, G. Tong, and Y. Zhou. 2021. A Virulent PEDV Strain FJzz1 with Genomic Mutations and Deletions at the High Passage Level Was Attenuated in Piglets via Serial Passage In Vitro. *Virologica Sinica*: 1–14. https://doi.org/10.1007/s12250-021-00368-w.
- Collin, E.A., S. Anbalagan, F. Okda, R. Batman, E. Nelson, and B.M. Hause. 2015. An inactivated vaccine made from a U.S. field isolate of porcine epidemic disease virus is immunogenic in pigs as demonstrated by a dose-titration. *BMC Veterinary Research* 11: 62. https://doi.org/10.1186/s12917-015-0357-1.
- Gerdts, V., and A. Zakhartchouk. 2017. Vaccines for porcine epidemic diarrhea virus and other swine coronaviruses. *Veterinary Microbiology* 206: 45–51. https://doi.org/10.1016/j.vetmic.2016.11.029.
- Guo, J., L. Fang, X. Ye, J. Chen, S. Xu, X. Zhu, Y. Miao, D. Wang, and S. Xiao. 2018. Evolutionary and genotypic analyses of global porcine epidemic diarrhea virus strains. *Transboundary and Emerging Diseases* 66 (1): 111–118. https:// doi.org/10.1111/tbed.12991.
- Hao, J., Y. Zhang, S. Fang, Z. Wen, X. Zhang, C. Xue, and Y. Cao. 2017. Evaluation of purified recombinant spike fragments for assessment of the presence of serum neutralizing antibodies against a variant strain of porcine epidemic diarrhea virus. *Virologica Sinica* 32 (4): 307–316. https://doi.org/10.1007/s122 50-017-3969-8.
- Hou, X., X. Jiang, Y. Jiang, L. Tang, Y. Xu, X. Qiao, L. Min, C. Wen, G. Ma, and Y. Li. 2018. Oral immunization against PEDV with recombinant Lactobacillus casei expressing dendritic cell-targeting peptide fusing COE protein of PEDV in piglets. *Viruses* 10 (3): 106. https://doi.org/10.3390/v10030106.
- Lee, C. 2015. Porcine epidemic diarrhea virus: An emerging and re-emerging epizootic swine virus. *Virology Journal* 12: 193. https://doi.org/10.1186/s12985-015-0421-2.
- Lee, S.H., D.-K. Yang, H.-H. Kim, and I.-S. Cho. 2018. Efficacy of inactivated variant porcine epidemic diarrhea virus vaccines in growing pigs. *Clinical and Experimental Vaccine Research* 7 (1): 61–69. https://doi.org/10.7774/cevr.2018. 7.1.61.
- Li, C., W. Li, E. Lucio de Esesarte, H. Guo, P. van den Elzen, E. Aarts, E. van den Born, P.J.M. Rottier, and B.-J. Bosch. 2017. Cell Attachment Domains of the Porcine Epidemic Diarrhea Virus Spike Protein Are Key Targets of Neutralizing

Antibodies. Journal of Virology 91 (12): e00273-e00217. https://doi.org/10.112 8/JVI.00273-17.

- Li, Q., O. Peng, T. Wu, Z. Xu, L. Huang, Y. Zhang, C. Xue, Z. Wen, Q. Zhou, and Y. Cao. 2018a. PED subunit vaccine based on COE domain replacement of flagellin domain D3 improved specific humoral and mucosal immunity in mice. *Vaccine* 36 (11): 1381–1388. https://doi.org/10.1016/j.vaccine.2018.01.086.
- Li, Q., Z. Xu, T. Wu, O. Peng, L. Huang, Y. Zhang, C. Xue, Z. Wen, Q. Zhou, and Y. Cao. 2018b. A flagellin-adjuvanted PED subunit vaccine improved protective efficiency against PEDV variant challenge in pigs. *Vaccine* 36 (29): 4228–4235. https://doi.org/10.1016/j.vaccine.2018.05.124.
- Liang, W., D. Zhou, C. Geng, K. Yang, Z. Duan, R. Guo, W. Liu, F. Yuan, Z. Liu, T. Gao, L. Zhao, D. Yoo, and Y. Tian. 2020. Isolation and evolutionary analyses of porcine epidemic diarrhea virus in Asia. *PeerJ* 8: e10114. https://doi.org/10. 7717/peerj.10114.
- Liao, C.W., C.A. Chen, C.N. Lee, Y.N. Su, M.C. Chang, M.H. Syu, C.Y. Hsieh, and W.F. Cheng. 2005. Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects. *Cancer Research* 65 (19): 9089–9098. https://doi.org/10.11 58/0008-5472.CAN-05-0958.
- Lin, C.M., LJ. Saif, D. Marthaler, and Q. Wang. 2016. Evolution, antigenicity and pathogenicity of global porcine epidemic diarrhea virus strains. *Virus Research* 226: 20–39. https://doi.org/10.1016/j.virusres.2016.05.023.
- Liu, X., Q. Zhang, L. Zhang, P. Zhou, J. Yang, Y. Fang, Z. Dong, D. Zhao, W. Li, J. Feng, B. Cui, Y. Zhang, and Y. Wang. 2019. A newly isolated Chinese virulent genotype Gllb porcine epidemic diarrhea virus strain: Biological characteristics, pathogenicity and immune protective effects as an inactivated vaccine candidate. *Virus Research* 259: 18–27. https://doi.org/10.1 016/j.virusres.2018.10.012.
- Ma, S., L. Wang, X. Huang, X. Wang, S. Chen, W. Shi, X. Qiao, Y. Jiang, L. Tang, Y. Xu, and Y. Li. 2018. Oral recombinant Lactobacillus vaccine targeting the intestinal microfold cells and dendritic cells for delivering the core neutralizing epitope of porcine epidemic diarrhea virus. *Microbial Cell Factories* 17 (1): 20. https://doi.org/10.1186/s12934-018-0861-7.
- Makadiya, N., R. Brownlie, J. van den Hurk, N. Berube, B. Allan, V. Gerdts, and A. Zakhartchouk. 2016. S1 domain of the porcine epidemic diarrhea virus spike protein as a vaccine antigen. *Virology Journal* 13: 57. https://doi.org/10.1186/s12985-016-0512-8.
- Martínez, F., V. Becerra, M. Muñoz, V. Loera, M. Ávila-Blanco, M. Medina-Rosales, and J. Ventura-Juárez. 2021. Evaluation of the PE ▲ III-LC3-KDEL3 Chimeric Protein of Entamoeba histolytica-Lectin as a Vaccine Candidate against Amebic Liver Abscess. *Journal of Immunology Research*. 2021: 6697900. https://doi.org/10.1155/2021/6697900.
- Oh, J., K.W. Lee, H.W. Choi, and C. Lee. 2014. Immunogenicity and protective efficacy of recombinant S1 domain of the porcine epidemic diarrhea virus spike protein. *Archives of Virology* 59 (11): 2977–2987. https://doi.org/10.1007/ s00705-014-2163-7.
- Park, J.E., K.J. Kang, J.H. Ryu, J.Y. Park, H. Jang, D.J. Sung, J.G. Kang, and H.J. Shin. 2018. Porcine epidemic diarrhea vaccine evaluation using a newly isolated strain from Korea. *Veterinary Microbiology* 221: 19–26. https://doi.org/10.1016/ j.vetmic.2018.05.012.
- Park, S.J., D.S. Song, and B.K. Park. 2013. Molecular epidemiology and phylogenetic analysis of porcine epidemic diarrhea virus (PEDV) field isolates in Korea. Archives of Virology 158 (7): 1533–1541. https://doi.org/10.1007/ s00705-013-1651-5.
- Pizzurro, F., F. Cito, G. Zaccaria, M. Spedicato, A. Cerella, M. Orsini, M. Forzan, N. D'Alterio, A. Lorusso, and M. Marcacci. 2018. Outbreak of porcine epidemic diarrhoea virus (PEDV) in Abruzzi region, central-Italy. *Veterinary Medicine and Science* 4 (2): 73–79. https://doi.org/10.1002/vms3.88.
- Reveles-Félix, S., R. Carreón-Nápoles, S. Mendoza-Elvira, V. Quintero-Ramírez, J. García-Sánchez, R. Martínez-Bautista, M. Saavedra-Montañez, J.J. Mosqueda Gualito, and J.I. Sánchez-Betancourt. 2020. Emerging strains of porcine epidemic diarrhoea virus (PEDv) in Mexico. *Transboundary and Emerging Diseases* 67 (2): 1035–1041. https://doi.org/10.1111/tbed.13426.
- Sun, D., X. Wang, S. Wei, J. Chen, and L. Feng. 2016. Epidemiology and vaccine of porcine epidemic diarrhea virus in China: a mini-review. *Journal of Veterinary Medical Science* 78 (3): 355–363. https://doi.org/10.1292/jvms.15-0446.
- Sun, J., Q. Li, C. Shao, Y. Ma, H. He, S. Jiang, Y. Zhou, Y. Wu, S. Ba, L. Shi, W. Fang, X. Wang, and H. Song. 2018. Isolation and characterization of Chinese porcine epidemic diarrhea virus with novel mutations and deletions in the S gene. *Veterinary Microbiology* 221: 81–89. https://doi.org/10.1016/j.vetmic.201 8.05.021.

- Wang, D., L. Fang, and S. Xiao. 2016. Porcine epidemic diarrhea in China. Virus Research 226: 7–13. https://doi.org/10.1016/j.virusres.2016.05.026.
- Wang, X.Y., C.J. Ji, X. Zhang, D.P. Xu, and D.L. Zhang. 2018. Infection, genetic and virulence characteristics of porcine epidemic diarrhea virus in northwest China. *Infection, Genetics and Evolution* 62: 34–39. https://doi.org/10.1016/j. meegid.2018.04.001.
- Yang, H.P., T.C. Wang, S.J. Wang, S.P. Chen, E. Wu, S.Q. Lai, H.W. Chang, and C.W. Liao. 2013. Recombinant chimeric vaccine composed of PRRSV antigens and truncated Pseudomonas exotoxin A (PE-K13). *Research in Veterinary Science* 95 (2): 742–751. https://doi.org/10.1016/j.rvsc.2013.05.003.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

